Scientific Publication

Evaluation of the therapeutic efficacy of praziquantel against schistosomes

author(s) Levecke, B. - Vlaminck, J. - Andriamaro, L. - Ame, S.
from UK Foreign, Commonwealth & Development Office (FCDO)
permalink open
themes
regions
  • Eastern Africa
  • Sub-Saharan Africa
  • Africa
  • World
  • South-Eastern Asia
  • Asia
  • Western Africa
  • Middle Africa
  • South America
  • Latin America and the Caribbean
  • Americas
citation

Levecke B, Vlaminck J, Andriamaro L, Ame S, Belizario V, Degarege A, Engels D, Erko B, Garba A, Kaatano G, Mekonnen Z, Montresor A, Olliaro P, Pieri O, Sacko M, Sam-Wobo S, Tchuem Tchuenté L, Webster J, Vercruysse J (2020). Evaluation of the therapeutic efficacy of praziquantel against schistosomes in seven countries with ongoing large-scale deworming programs. Int J Parasitol Drugs Drug Resist. 14:183-187

Publications and datasets provided via GARDIAN

Abstract

The World Health Organization (WHO) recommends periodic assessment of the therapeutic efficacy of praziquantel (PZQ) to detect reduced efficacy that may arise from drug resistance in schistosomes. In this multi-country study (2014), we assessed the therapeutic efficacy of a single oral dose of PZQ (40 mg/kg) against Schistosoma mansoni (Brazil, Cameroon, Ethiopia, Mali, Madagascar and Tanzania), S. haematobium (Cameroon, Ethiopia, Mali, Tanzania and Zanzibar) and S. japonicum (the Philippines) infections in school-aged children, across a total of 12 different trials. This is a publication arising from the Zoonoses and Emerging Livestock Systems (ZELS) programme

Open original